Breast cancer remains a leading cause of malignancy-related mortality among women globally, with triple-negative breast cancer (TNBC) posing a significant clinical challenge due to its aggressive nature and early metastatic potential. Previous studies have implicated obesity in driving tumor progression, often associating it with diminished therapeutic responses and poor survival outcomes.

A peptide that successfully targeted and killed metastatic cancer cells in mice may open the door to developing more efficient ways to detect and treat metastatic breast cancer in humans, UTHealth Houston researchers have discovered. 

For many patients with breast cancer, deciding whether cancer has spread to nearby lymph nodes still depends on labor-intensive pathology workflows that require tissue cutting, staining, and expert interpretation.